Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 2, 2013, Pages 280-289

  Wüthrich, Rudolf P ^a   Chonchol, Michel ^b   Covic, Adrian ^c   Gaillard, Sylvain ^d   Chong, Edward ^d   Tumlin, James A ^e  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF COLORADO   (United States)

^c C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^d Vifor (International) Inc   (Switzerland)

^e UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; IRON BASED PHOSPHATE BINDER PA21; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTICLE; BLOOD SAMPLING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FECES COLOR; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTENSION; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VOMITING;

FEMALE; FERRIC COMPOUNDS; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 84875035936     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08230811     Document Type: Article

References (13)

1. Coladonato JA: Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol 16[Suppl 2]: S107-S114, 2005
2. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33: 694-701, 1999
3. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68: 1815-1824, 2005
4. Chertow GM, Burke SK, Raggi P; Treat to GoalWorking Group;: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002
5. Kidney Disease Improving Global Outcomes (KDIGO): Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Chapter 3.1: Diagnosis of CKD-MBD: Biochemical abnormalities. Kidney Int Supp 76[Suppl 113]: S22-S49, 2009
6. Renvela (sevelamer carbonate). Prescribing information. Cambridge, MA, Genzyme Corporation, 2009. Available at: http://www.renvela.com/-/media/Files/RenvelaUS/RV382_Renvela_PI_08.2011.pdf. Accessed October 19, 2012
7. Fosrenol. Summary of product characteristics. Hampshire, UK, Shire Pharmaceutical Ltd, 2009. Available at: http://emc.medicines. org.uk/document.aspx?documentId=19617
8. Mohammed IA, Hutchison AJ: Phosphate binding therapy in dialysis patients: Focus on lanthanum carbonate. Ther Clin Risk Manag 4: 887-893, 2008
9. Pennick M, Dennis K, Damment SJP: Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J Clin Pharmacol 46: 738-746, 2006
10. Damment SJP, Pennick M: Clinical pharmacokinetics of the phosphate binder lanthanumcarbonate. Clin Pharmacokinet 47: 553-563, 2008
11. Wilhelm M, Funk F, Gaillard S: PA21, a novel iron-based phosphate binder, has high phosphate binding capacity and low iron release in vitro across a physiological pH range [Abstract]. Poster presentation at KidneyWeek 2012, SanDiego, CA., October 30-November 4, 2012
12. Geisser P, Philipp E: PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol 74: 4-11, 2010
13. National Kidney Foundation: K/DOQI clinical practice guidelines for bonemetabolismand disease in chronic kidney disease. Am J Kidney Dis 42[Suppl 3]: S1-S201, 2003